Sonstiges: |
- Nachgewiesen in: MEDLINE
- Sprachen: English
- Publication Type: Journal Article
- Language: English
- [Bull Exp Biol Med] 2022 Nov; Vol. 174 (1), pp. 104-108. <i>Date of Electronic Publication: </i>2022 Nov 28.
- MeSH Terms: Breast Neoplasms* / drug therapy ; Breast Neoplasms* / surgery ; Breast Neoplasms* / therapy ; Cytokines* / metabolism ; DNA* / administration & dosage ; Lymph Nodes* / metabolism ; Mammary Neoplasms, Animal* / drug therapy ; Mammary Neoplasms, Animal* / surgery ; Mammary Neoplasms, Animal* / therapy ; Adjuvants, Immunologic* / administration & dosage ; Female ; Chemokines / metabolism ; Interleukin-4 / metabolism ; Lymph / metabolism ; Animals ; Rats ; Rats, Wistar ; T-Lymphocytes / immunology
- References: DeSantis CE, Ma J, Gaudet MM, Newman LA, Miller KD, Goding Sauer A, Jemal A, Siegel RL. Breast cancer statistics, 2019. CA Cancer J. Clin. 2019;69(6):438-451. doi: https://doi.org/10.3322/caac.215839 . (PMID: 10.3322/caac.215839) ; Dhesy-Thind S, Fletcher GG, Blanchette PS, Clemons MJ, Dillmon MS, Frank ES, Gandhi S, Gupta R, Mates M, Moy B, Vandenberg T, Van Poznak CH. Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: a Cancer Care Ontario and American Society of Clinical Oncology Clinical Practice Guideline. J. Clin. Oncol. 2017;35(18):2062-2081. doi: https://doi.org/10.1200/JCO.2016.70.7257. (PMID: 10.1200/JCO.2016.70.7257) ; Poveshchenko AF, Kazakov OV, Orlov NB, Poveshchenko OV, Kim II, Bondarenko NA, Solovieva IG, Strunkin DN, Kabakov AV, Rayter TV, Lykov AP, Bogachev SS, Pokushalov EA, Konenkov VI. Lymph cytokines as markers oncogenesis and effective treatment of experimental breast cancer Wistar rat. Patol. Fiziol. Eksper. Ter. 2016;60(3):68-75. Russian. ; Bridge JA, Lee JC, Daud A, Wells JW, Bluestone JA. Cytokines, chemokines, and other biomarkers of response for checkpoint inhibitor therapy in skin cancer. Front. Med. (Lausanne). 2018;5:351. doi: https://doi.org/10.3389/fmed.2018.00351. (PMID: 10.3389/fmed.2018.00351) ; Bogachev SS, Proskurina AS, Gvozdeva TS, Potter EA, Dolgova EV, Orishchenko KE, Nikolin VP, Popova NA, Chernikh ER, Ostanin AA, Leplina OYu, Varaksin NA, Ryabicheva TG, Dvornichenko VV, Ponomarenko DM, Sidorov SV. Results of phase II clinical trials of the Panagen preparation and 5-year relapse-free survival of patients included in the study. Ross. Bioter. Zh. 2016;15(1):13-14. Russian. ; Proskurina AS, Alyamkina EA, Dolgova EV, Nikolin VP, Popova NA, Gvozdeva TS, Orishchenko KE, Sidorov SV, Chernykh ER, Ostanin AA, Leplina OYu, Dvornichenko VV, Ponomarenko DM, Soldatova GS, Varaksin NA, Ryabicheva TG, Zagrebelnij SN, Rogachev VA, Bogachev SS, Shurdov MA. Leykostimulatory and antitumor effect of the human double-stranded DNA preparation “Panagen” in experiments and clinical trials. I. Leykostimulatory and antitumor effect of the preparation “Panagen” in experiments. Vestn. Novosib. Gos. Univer. Ser. Biol. Klin. Med. 2013;11(4):67-82. Russian. ; Kabakov AV, Lykov AP, Morozov DV, Kazakov OV, Poveshchenko AF, Raiter TV, Strunkin DN, Konenkov VI. Phenotypical characteristics of chemically induced mammary tumor. Bull. Exp. Biol. Med. 2017;163(4):490-492. doi: https://doi.org/10.1007/s10517-017-3835-6. (PMID: 10.1007/s10517-017-3835-6) ; Takatsu K. Interleukin 5 and B cell differentiation. Cytokine Growth Factor Rev. 1998;9(1):25-35. doi: https://doi.org/10.1016/s1359-6101(97)00034-8. (PMID: 10.1016/s1359-6101(97)00034-8) ; Nakanishi K. Unique action of interleukin-18 on T cells and other immune cells. Front. Immunol. 2018;9:763. doi: https://doi.org/10.3389/fimmu.2018.00763. (PMID: 10.3389/fimmu.2018.00763) ; Read KA, Powell MD, McDonald PW, Oestreich KJ. IL-2, IL-7, and IL-15: multistage regulators of CD4(+) T helper cell differentiation. Exp. Hematol. 2016;44(9):799-808. doi: https://doi.org/10.1016/j.exphem.2016.06.003. (PMID: 10.1016/j.exphem.2016.06.003) ; Gagnon J, Ramanathan S, Leblanc C, Cloutier A, McDonald PP, Ilangumaran S. IL-6, in synergy with IL-7 or IL-15, stimulates TCR-independent proliferation and functional differentiation of CD8+ T lymphocytes. J. Immunol. 2008;180(12):7958-7968. doi: https://doi.org/10.4049/jimmunol.180.12.7958. (PMID: 10.4049/jimmunol.180.12.7958) ; Atreya R, Mudter J, Finotto S, Müllberg J, Jostock T, Wirtz S, Schütz M, Bartsch B, Holtmann M, Becker C, Strand D, Czaja J, Schlaak JF, Lehr HA, Autschbach F, Schürmann G, Nishimoto N, Yoshizaki K, Ito H, Kishimoto T, Galle PR, Rose-John S, Neurath MF. Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in Crohn disease and experimental colitis in vivo. Nat. Med. 2000;6(5):583-588. doi: https://doi.org/10.1038/75068. (PMID: 10.1038/75068) ; Su H, Lei CT, Zhang C. Interleukin-6 signaling pathway and its role in kidney disease: an update. Front. Immunol. 2017;8:405. doi: https://doi.org/10.3389/fimmu.2017.00405. (PMID: 10.3389/fimmu.2017.00405) ; Boyman O, Sprent J. The role of interleukin-2 during homeostasis and activation of the immune system. Nat. Rev. Immunol. 2012;12(3):180-190. doi: https://doi.org/10.1038/nri3156. (PMID: 10.1038/nri3156)
- Contributed Indexing: Keywords: breast cancer; chemotherapy; fragmented human DNA; lymph cytokines; surgical treatment
- Substance Nomenclature: 0 (Chemokines) ; 0 (Cytokines) ; 9007-49-2 (DNA) ; 207137-56-2 (Interleukin-4) ; 0 (Adjuvants, Immunologic)
- Entry Date(s): Date Created: 20221127 Date Completed: 20221221 Latest Revision: 20221221
- Update Code: 20240513
|